The majority of older women in nursing homes are likely to be deficient in vitamin D during winter months, and those with the lowest levels are at a significantly increased risk of death, according to a study published online February 8, in the Journal of Clinical Endocrinology.
The Academy of Managed Care Pharmacy (AMCP) is pleased that FDA is exploring the public health benefit of approving certain drugs that would otherwise require a prescription for nonprescription use under conditions of safe use, an AMCP official said in written testimony Thursday.
FDA approved the first generic versions of Boniva (ibandronate) tablets, a once-monthly product to treat or prevent osteoporosis in women after menopause.
The final rule for Medicaid eligibility in the Affordable Care Act (ACA) will ensure health coverage for millions of Americans, according to Friday's announcement by Health and Human Services Secretary Kathleen Sebelius.
The FDA's Center for Drug Evaluation and Research released a new draft guidance on how it develops and classifies drug-safety issues.
The time from investigational new drug application filing to NDA/BLA approval by FDA of drugs for central nervous system disorders and the subsequent regulatory approval can take 35% longer than other therapeutic categories, according to a recent analysis published in the March/April Tufts Center for the Study of Drug Development Impact Report.
Patients' rheumatoid arthritis symptoms improved after adding prednisone at the start of a methotrexate-based treatment strategy, according to research published in the March 6 issue of the Annals of Internal Medicine.
Postmenopausal women with a higher intake of trans fat have a higher incidence of ischemic stroke, but aspirin may reduce the adverse effects of trans fat, according to a new study.
Veterans of Afghanistan and Iraq with mental health issues, especially post-traumatic stress disorder (PTSD), were more likely to receive high-risk opioids for pain, and those with PTSD were more likely to suffer adverse clinical outcomes, according to a new study.
An experimental diabetes drug, TAK-875, demonstrated its ability to improve blood-sugar control with a low risk of hypoglycemia, according to phase 2 study results published online February 27 in The Lancet.
A mathematical model that uses laboratory values commonly available on admission can help physicians estimate acetaminophen (APAP: N-acetyl-para-aminophenol) overdose amount, time elapsed since overdose, and potential outcome, according to a study published online February 13 in Hepatology.
FDA has approved a new indication for estradiol valerate and estradiol valerate/dienogest (Natazia, Bayer HealthCare Pharmaceuticals) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus.
Federal and state governments may soon be looking to managed care for a comprehensive solution.
With increased coverage under the Patient Protection and Affordable Care Act (PPACA), insurers are expecting an influx of enrollees.
MemorialCare Health System has announced the affiliation of Greater Newport Physicians with its MemorialCare Medical Foundation and the acquisition of Nautilus Healthcare Management Group, Greater Newport?s affiliated management services organization.
Differences in health status explain much of the regional variation in spending for privately insured people, but differences in provider prices-especially for hospital care-also play a key role.
Research indicates paying for a patient's entire care episode rather than individually for every test and treatment for certain procedures could save payers money.
Gay marriage makes headlines, but health coverage for domestic partners is quietly becoming more common as top employers seek ways to further define their corporate culture and provide attractive benefit plans.
With a year-end deadline looming, health Insurance companies who want to participate in PPACA's state-run exchanges have to be ready for anything.
FDA has approved alendronate sodium (Binosto, EffRx Pharmaceuticals) effervescent tablets, the first effervescent osteoporosis treatment in a buffered solution.
Teva/IVAX Pharmaceuticals gained FDA approval for the first generic version of Lexapro (Forest) to treat both depression and generalized anxiety disorder in adults. The company will have 180 days to exclusively sell the product.
FDA approved the first cell-based product made from allogeneic human cells and bovine collagen (Gintuit, Organogenesis) for in the treatment of mucogingival conditions in adults, the agency announced Friday.
Antipsychotic medication should be used on elderly dementia patients only in cases of clear need, authors of a recent study said, but they found that some antipsychotics are more dangerous than others after examining data from thousands of nursing-home residents aged 65 or older.
A treat-and-extend regimen of intravitreal bevacizumab (Avastin, Genentech) produced "significant visual improvements" for eyes with neovascular age-related macular degeneration, according to an article published in the March issue of the American Journal of Ophthalmology.
The 2012 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the evidence-based position statement published by NAMS in 2010 regarding recommendations for hormone therapy for postmenopausal women.
New guidelines for the use of the quadrivalent human papillomavirus vaccine, published by the American Academy of Pediatrics, recommend for the first time vaccinating adolescent boys as well as girls.
An FDA advisory panel voted 12-2 to recommend approval of aclidinium bromide (Forest Laboratories and Almirall SA) 400 µg twice daily for the long-term maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
FDA has approved lucinactant (Surfaxin, Discovery Labs) for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. Surfaxin is the first synthetic, peptide-containing surfactant approved for use in neonatal medicine.
FDA has approved lucinactant (Surfaxin, Discovery Labs) for the prevention of respiratory distress syndrome (RDS) in premature infants at high risk for RDS. Surfaxin is the first synthetic, peptide-containing surfactant approved for use in neonatal medicine.
Thursday, FDA updated its recommendations concerning drug-drug interactions between protease inhibitors and statins, warning of an increased risk of muscle injury (myopathy). The most serious form of myopathy, rhabdomyolysis, can damage kidneys and lead to kidney failure, which can be fatal.